Liu Yingyu, Kou Changgui, Su Yingying, Zhang Yangyu, You Yueyue, Zhang Lili, Wang Mohan, Fu Yingli, Ren Xiaojun, Yang Yanming
Department of Epidemiology and Biostatistics, School of Public Health, Jilin University.
Department of Radiotherapy, Second Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Onco Targets Ther. 2017 Jun 13;10:2971-2981. doi: 10.2147/OTT.S137474. eCollection 2017.
The goal of this study was to evaluate the efficacy and safety of modified (accelerated and/or hyperfractionated) radiotherapy in the treatment of esophageal carcinoma, compared with conventional radiotherapy.
Studies published in the PubMed, Cochrane Library, EMBASE, CBM, VIP, CNKI and Wanfang databases in the most recent two decades were searched for use in this meta-analysis. Only randomized controlled trials were included. The heterogeneity analysis and calculation of the pooled odds ratio (OR) were performed using RevMan 5.3 software. The assessment of publication bias and sensitivity analyses was conducted using Stata 13.0 software.
Twenty trials with a total of 1,742 Chinese patients who met the inclusion criteria were included. The pooled results showed that modified radiotherapy improved the response rate compared with conventional schedules (OR =3.90, 95% confidence interval [CI]: 2.47-6.16, <0.001). Favorable results were observed for the 1-year (OR =2.58, 95% CI: 2.05-3.26, <0.001), 3-year (OR =2.30, 95% CI: 1.83-2.89, <0.001) and 5-year (OR =2.36, 95% CI: 1.74-3.21, <0.001) overall survival and for the 1-year (OR =2.46, 95% CI: 1.72-3.51, <0.001), 3-year (OR =2.08, 95% CI: 1.49-2.90, <0.001) and 5-year (OR =2.15, 95% CI: 1.38-3.34, <0.001) overall local control rate in the modified fractionation radiotherapy group. However, the altered radiotherapy increased the risk of acute radiation esophagitis (OR =1.70, 95% CI: 1.27-2.28, <0.001) and acute radiation tracheitis (OR =1.47, 95% CI: 1.09-1.99, =0.01). No significant differences in the risk of esophageal perforation (OR =1.30, 95% CI: 0.51-3.32, =0.58) or esophagorrhagia (OR =0.88, 95% CI: 0.41-1.88, =0.74) were found between the two groups.
Chinese patients with squamous cell esophagus carcinomas gained a significant benefit in terms of the response rate, survival and local control rates from the modified fractionation radiotherapy, but also had an increased risk of acute radiation reactions. Otherwise, there was no observed statistically significant difference in terms of early adverse reactions.
本研究旨在评估改良(加速和/或超分割)放疗对比传统放疗治疗食管癌的疗效和安全性。
检索PubMed、Cochrane图书馆、EMBASE、CBM、VIP、CNKI和万方数据库中近二十年发表的研究用于本荟萃分析。仅纳入随机对照试验。使用RevMan 5.3软件进行异质性分析并计算合并比值比(OR)。使用Stata 13.0软件进行发表偏倚评估和敏感性分析。
纳入20项试验,共1742例符合纳入标准的中国患者。汇总结果显示,与传统放疗方案相比,改良放疗提高了缓解率(OR = 3.90,95%置信区间[CI]:2.47 - 6.16,<0.001)。在改良分割放疗组中,1年(OR = 2.58,95% CI:2.05 - 3.26,<0.001)、3年(OR = 2.30,95% CI:1.83 - 2.89,<0.001)和5年(OR = 2.36,95% CI:1.74 - 3.21,<0.001)总生存率以及1年(OR = 2.46,95% CI:1.72 - 3.51,<0.001)、3年(OR = 2.08,95% CI:1.49 - 2.90,<0.001)和5年(OR = 2.15,95% CI:1.38 - 3.34,<0.001)总局部控制率方面观察到良好结果。然而,改变后的放疗增加了急性放射性食管炎(OR = 1.70,95% CI:1.27 - 2.28,<0.001)和急性放射性气管炎(OR = 1.47,95% CI:1.09 - 1.99,=0.01)的风险。两组之间在食管穿孔风险(OR = 1.30,95% CI:0.51 - 3.32,=0.58)或食管出血风险(OR = 0.88,95% CI:0.41 - 1.88,=0.74)方面未发现显著差异。
中国鳞状细胞食管癌患者在缓解率、生存率和局部控制率方面从改良分割放疗中获得显著益处,但急性放射反应风险也增加。此外,在早期不良反应方面未观察到统计学显著差异。